10-Q 1 hsic-20240629.htm HENRY SCHEIN 2Q 2024 10-Q hsic-20240629
false 0001000228 --12-28 none 480000000 0.01 0.01 1000000 33.33 0.004 0 Q2 NASDAQ P5Y December 24, 2012 December 24, 2024 June 16, 2017 June 16, 2027 September 15, 2017 September 15, 2029 January 2, 2018 January 2, 2028 September 2, 2020 September 2, 2030 June 2, 2021 June 2, 2031 June 2, 2021 June 2, 2033 May 4, 2023 May 4, 2028 May 4, 2023 May 4, 2030 May 4, 2023 May 4, 2033 May 4, 2023 May 4, 2033 P3Y P4Y P3Y P6Y P10Y 0001000228 2023-01-01 2023-07-01 0001000228 2023-12-31 2024-06-29 0001000228 2023-12-30 0001000228 2023-01-01 2023-12-30 0001000228 2024-06-29 0001000228 us-gaap:RetainedEarningsMember 2023-12-31 2024-06-29 0001000228 us-gaap:LoansPayableMember srt:MinimumMember 2023-12-30 0001000228 us-gaap:RevolvingCreditFacilityMember 2023-12-30 0001000228 us-gaap:CommonStockMember 2023-12-31 2024-06-29 0001000228 us-gaap:LoansPayableMember srt:MaximumMember 2024-06-29 0001000228 2022-12-31 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 2024-06-29 0001000228 us-gaap:NoncontrollingInterestMember 2023-12-31 2024-06-29 0001000228 us-gaap:RevolvingCreditFacilityMember 2024-06-29 0001000228 us-gaap:LoansPayableMember srt:MaximumMember 2023-12-30 0001000228 us-gaap:LoansPayableMember srt:MinimumMember 2024-06-29 0001000228 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 2024-06-29 0001000228 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 2024-06-29 0001000228 us-gaap:RetainedEarningsMember 2024-03-31 2024-06-29 0001000228 us-gaap:EquityMethodInvesteeMember 2023-12-31 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities8Member 2024-06-29 0001000228 hsic:HealthCareDistributionMember 2023-01-01 2023-07-01 0001000228 hsic:TechnologyAndValueAddedServicesMember 2023-01-01 2023-07-01 0001000228 us-gaap:CommonStockMember 2024-03-31 2024-06-29 0001000228 hsic:OtherShortTermCreditLinesMember 2023-12-30 0001000228 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-07-01 0001000228 hsic:PrivatePlacementFacilitiesMember 2023-12-30 0001000228 hsic:USTradeAccountsReceivableSecuritizationMember 2023-12-30 0001000228 us-gaap:LoansPayableMember 2024-06-29 0001000228 us-gaap:LoansPayableMember 2023-12-30 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities1Member 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities2Member 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities3Member 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities4Member 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities5Member 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities6Member 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities7Member 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities1Member 2023-12-31 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities2Member 2023-12-31 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities3Member 2023-12-31 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities4Member 2023-12-31 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities5Member 2023-12-31 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities6Member 2023-12-31 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities7Member 2023-12-31 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities8Member 2023-12-31 2024-06-29 0001000228 2024-07-29 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember 2023-01-01 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:InternationalMember 2023-01-01 2023-07-01 0001000228 srt:NorthAmericaMember hsic:TechnologyAndValueAddedServicesMember 2023-01-01 2023-07-01 0001000228 hsic:InternationalMember hsic:TechnologyAndValueAddedServicesMember 2023-01-01 2023-07-01 0001000228 srt:NorthAmericaMember 2023-01-01 2023-07-01 0001000228 hsic:InternationalMember 2023-01-01 2023-07-01 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember hsic:DentalMember 2023-01-01 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:DentalMember hsic:InternationalMember 2023-01-01 2023-07-01 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember hsic:MedicalMember 2023-01-01 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:MedicalMember hsic:InternationalMember 2023-01-01 2023-07-01 0001000228 us-gaap:EquityMethodInvesteeMember 2023-01-01 2023-07-01 0001000228 2024-03-31 2024-06-29 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 2024-06-29 0001000228 us-gaap:NoncontrollingInterestMember 2024-03-31 2024-06-29 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember hsic:DentalMember 2023-12-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:DentalMember hsic:InternationalMember 2023-12-31 2024-06-29 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember hsic:MedicalMember 2023-12-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:MedicalMember hsic:InternationalMember 2023-12-31 2024-06-29 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember 2023-12-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:InternationalMember 2023-12-31 2024-06-29 0001000228 srt:NorthAmericaMember hsic:TechnologyAndValueAddedServicesMember 2023-12-31 2024-06-29 0001000228 hsic:InternationalMember hsic:TechnologyAndValueAddedServicesMember 2023-12-31 2024-06-29 0001000228 srt:NorthAmericaMember 2023-12-31 2024-06-29 0001000228 hsic:InternationalMember 2023-12-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember 2023-12-31 2024-06-29 0001000228 hsic:TechnologyAndValueAddedServicesMember 2023-12-31 2024-06-29 0001000228 hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember 2023-12-31 2024-06-29 0001000228 hsic:NonEmployeeDirectorStockIncentivePlanMember hsic:TimeBasedRestrictedStockRestrictedUnitsMember 2023-12-31 2024-06-29 0001000228 us-gaap:EmployeeStockOptionMember 2023-12-31 2024-06-29 0001000228 us-gaap:EmployeeStockOptionMember 2023-12-31 2024-06-29 0001000228 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 2024-06-29 0001000228 us-gaap:RoyaltyAgreementsMember hsic:InternetBrandsIncMember 2023-12-31 2024-06-29 0001000228 hsic:TimeBasedRestrictedStockRestrictedUnitsMember 2023-12-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember 2024-06-29 0001000228 hsic:TechnologyAndValueAddedServicesMember 2024-06-29 0001000228 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:AssetPledgedAsCollateralMember 2023-12-30 0001000228 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:RecourseMember 2023-12-30 0001000228 srt:NorthAmericaMember 2024-03-31 2024-06-29 0001000228 hsic:InternationalMember 2024-03-31 2024-06-29 0001000228 us-gaap:EquityMethodInvesteeMember 2024-03-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember 2024-03-31 2024-06-29 0001000228 hsic:TechnologyAndValueAddedServicesMember 2024-03-31 2024-06-29 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember 2024-03-31 2024-06-29 0001000228 srt:NorthAmericaMember hsic:TechnologyAndValueAddedServicesMember 2024-03-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:InternationalMember 2024-03-31 2024-06-29 0001000228 hsic:InternationalMember hsic:TechnologyAndValueAddedServicesMember 2024-03-31 2024-06-29 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember hsic:DentalMember 2024-03-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:DentalMember hsic:InternationalMember 2024-03-31 2024-06-29 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember hsic:MedicalMember 2024-03-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:MedicalMember hsic:InternationalMember 2024-03-31 2024-06-29 0001000228 2023-04-02 2023-07-01 0001000228 hsic:HealthCareDistributionMember 2023-04-02 2023-07-01 0001000228 hsic:TechnologyAndValueAddedServicesMember 2023-04-02 2023-07-01 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember 2023-04-02 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:InternationalMember 2023-04-02 2023-07-01 0001000228 srt:NorthAmericaMember hsic:TechnologyAndValueAddedServicesMember 2023-04-02 2023-07-01 0001000228 hsic:InternationalMember hsic:TechnologyAndValueAddedServicesMember 2023-04-02 2023-07-01 0001000228 srt:NorthAmericaMember 2023-04-02 2023-07-01 0001000228 hsic:InternationalMember 2023-04-02 2023-07-01 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember hsic:DentalMember 2023-04-02 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:DentalMember hsic:InternationalMember 2023-04-02 2023-07-01 0001000228 srt:NorthAmericaMember hsic:HealthCareDistributionMember hsic:MedicalMember 2023-04-02 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:MedicalMember hsic:InternationalMember 2023-04-02 2023-07-01 0001000228 us-gaap:EquityMethodInvesteeMember 2023-04-02 2023-07-01 0001000228 hsic:PrivatePlacementFacilitiesMember 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember 2023-12-31 2024-06-29 0001000228 srt:MinimumMember hsic:PrivatePlacementFacilitiesMember 2023-12-31 2024-06-29 0001000228 srt:MaximumMember hsic:PrivatePlacementFacilitiesMember 2023-12-31 2024-06-29 0001000228 us-gaap:OtherLiabilitiesMember 2024-06-29 0001000228 us-gaap:OtherLiabilitiesMember 2023-12-30 0001000228 hsic:HealthCareDistributionMember 2023-12-30 0001000228 hsic:TechnologyAndValueAddedServicesMember 2023-12-30 0001000228 hsic:TimeBasedRestrictedStockRestrictedUnitsMember 2023-12-30 0001000228 hsic:TimeBasedRestrictedStockRestrictedUnitsMember 2024-06-29 0001000228 hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember 2023-12-30 0001000228 hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember 2024-06-29 0001000228 us-gaap:EmployeeStockOptionMember 2024-03-31 2024-06-29 0001000228 us-gaap:EmployeeStockOptionMember 2023-04-02 2023-07-01 0001000228 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 2024-06-29 0001000228 us-gaap:RestrictedStockUnitsRSUMember 2023-04-02 2023-07-01 0001000228 us-gaap:EquityMethodInvesteeMember 2024-06-29 0001000228 hsic:ActionsConsolidatedInTheMultiDistrictLitigationMember 2023-01-01 2023-12-30 0001000228 us-gaap:NoncontrollingInterestMember 2023-12-30 0001000228 us-gaap:CommonStockMember 2023-12-30 0001000228 us-gaap:RetainedEarningsMember 2023-12-30 0001000228 us-gaap:AdditionalPaidInCapitalMember 2023-12-30 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-30 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities9Member 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities10Member 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities11Member 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities9Member 2023-12-31 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities10Member 2023-12-31 2024-06-29 0001000228 hsic:PrivatePlacementFacilitiesMember hsic:PrivatePlacementFacilities11Member 2023-12-31 2024-06-29 0001000228 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-07-01 0001000228 hsic:TermCreditAgreementMember 2023-12-30 0001000228 2024-03-30 0001000228 us-gaap:NoncontrollingInterestMember 2024-03-30 0001000228 us-gaap:CommonStockMember 2024-03-30 0001000228 us-gaap:RetainedEarningsMember 2024-03-30 0001000228 us-gaap:AdditionalPaidInCapitalMember 2024-03-30 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-30 0001000228 us-gaap:EquityMethodInvesteeMember 2023-12-30 0001000228 hsic:BiotechDentalMember 2023-12-31 2024-06-29 0001000228 hsic:SINImplantSystemMember 2023-07-05 0001000228 hsic:BiotechDentalMember 2023-04-05 0001000228 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember srt:MinimumMember 2023-12-30 0001000228 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember srt:MaximumMember 2023-12-30 0001000228 hsic:BiotechDentalMember 2023-07-02 2024-03-30 0001000228 hsic:BiotechDentalMember 2024-03-30 0001000228 hsic:CustomerRelationshipsAndListsMember hsic:BiotechDentalMember 2023-04-05 2023-04-05 0001000228 us-gaap:TrademarksAndTradeNamesMember hsic:BiotechDentalMember 2023-04-05 2023-04-05 0001000228 hsic:BiotechDentalMember hsic:ProductDevelopmentMember 2023-04-05 2023-04-05 0001000228 hsic:BiotechDentalMember 2023-04-05 2023-04-05 0001000228 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-06-29 0001000228 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-30 0001000228 us-gaap:RevolvingCreditFacilityMember 2021-08-20 2021-08-20 0001000228 us-gaap:RevolvingCreditFacilityMember 2023-12-31 2024-06-29 0001000228 hsic:OtherShortTermCreditLinesMember 2024-06-29 0001000228 hsic:TermCreditAgreementMember 2023-12-31 2024-06-29 0001000228 hsic:TermCreditAgreementMember 2024-06-29 0001000228 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember hsic:TermCreditAgreementMember 2024-06-29 0001000228 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember hsic:TermCreditAgreementMember 2023-12-31 2024-06-29 0001000228 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember hsic:TermCreditAgreementMember 2023-12-30 0001000228 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember hsic:TermCreditAgreementMember 2023-01-01 2023-12-30 0001000228 us-gaap:InterestRateSwapMember hsic:TermCreditAgreementMember 2023-12-30 0001000228 hsic:USTradeAccountsReceivableSecuritizationMember 2023-12-31 2024-06-29 0001000228 hsic:USTradeAccountsReceivableSecuritizationMember 2024-06-29 0001000228 hsic:USTradeAccountsReceivableSecuritizationMember hsic:AverageAssetBackedCommercialPaperRateMember 2024-06-29 0001000228 hsic:USTradeAccountsReceivableSecuritizationMember hsic:AverageAssetBackedCommercialPaperRateMember 2023-12-31 2024-06-29 0001000228 hsic:USTradeAccountsReceivableSecuritizationMember hsic:AverageAssetBackedCommercialPaperRateMember 2023-12-30 0001000228 hsic:USTradeAccountsReceivableSecuritizationMember hsic:AverageAssetBackedCommercialPaperRateMember 2023-01-01 2023-12-30 0001000228 srt:MaximumMember 2024-06-29 0001000228 hsic:OtherHospitalsLocatedThroughoutFloridaMember 2023-12-31 2024-06-29 0001000228 us-gaap:SegmentContinuingOperationsMember hsic:ActionsConsolidatedInTheMultiDistrictLitigationMember 2023-01-01 2023-12-30 0001000228 hsic:EmployeesAndMinorityShareholdersMember hsic:OperatingLeaseLiabilitiesCurrentMember hsic:RelatedPartyConcentrationRiskMember 2023-01-01 2023-12-30 0001000228 hsic:EmployeesAndMinorityShareholdersMember hsic:OperatingLeaseLiabilitiesNoncurrentMember hsic:RelatedPartyConcentrationRiskMember 2023-01-01 2023-12-30 0001000228 hsic:SINImplantSystemMember 2023-07-05 2023-07-05 0001000228 2023-07-01 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-29 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-29 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-29 0001000228 us-gaap:FairValueMeasurementsRecurringMember 2024-06-29 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-29 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-29 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-29 0001000228 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-29 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-30 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-30 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-30 0001000228 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-30 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-06-29 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-06-29 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-06-29 0001000228 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2024-06-29 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2023-12-30 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2023-12-30 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2023-12-30 0001000228 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2023-12-30 0001000228 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0001000228 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0001000228 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0001000228 us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0001000228 hsic:InternetBrandsIncMember 2023-12-30 0001000228 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:AssetPledgedAsCollateralMember 2024-06-29 0001000228 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:RecourseMember 2024-06-29 0001000228 us-gaap:NoncontrollingInterestMember 2024-06-29 0001000228 us-gaap:CommonStockMember 2024-06-29 0001000228 us-gaap:RetainedEarningsMember 2024-06-29 0001000228 us-gaap:AdditionalPaidInCapitalMember 2024-06-29 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-29 0001000228 2023-04-01 0001000228 us-gaap:CommonStockMember 2023-04-01 0001000228 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 0001000228 us-gaap:RetainedEarningsMember 2023-04-01 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 0001000228 us-gaap:NoncontrollingInterestMember 2023-04-01 0001000228 us-gaap:RetainedEarningsMember 2023-04-02 2023-07-01 0001000228 us-gaap:NoncontrollingInterestMember 2023-04-02 2023-07-01 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-02 2023-07-01 0001000228 us-gaap:AdditionalPaidInCapitalMember 2023-04-02 2023-07-01 0001000228 us-gaap:CommonStockMember 2023-04-02 2023-07-01 0001000228 us-gaap:CommonStockMember 2023-07-01 0001000228 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 0001000228 us-gaap:RetainedEarningsMember 2023-07-01 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 0001000228 us-gaap:NoncontrollingInterestMember 2023-07-01 0001000228 us-gaap:CommonStockMember 2022-12-31 0001000228 us-gaap:CommonStockMember 2023-01-01 2023-07-01 0001000228 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001000228 us-gaap:RetainedEarningsMember 2022-12-31 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001000228 us-gaap:NoncontrollingInterestMember 2022-12-31 0001000228 us-gaap:RetainedEarningsMember 2023-01-01 2023-07-01 0001000228 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-07-01 0001000228 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-07-01 0001000228 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:DentalMember 2023-01-01 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:MedicalMember 2023-01-01 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:DentalMember 2023-12-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:MedicalMember 2023-12-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:DentalMember 2023-04-02 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:MedicalMember 2023-04-02 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:DentalMember 2024-03-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:MedicalMember 2024-03-31 2024-06-29 0001000228 hsic:TriMedIncMember 2023-12-31 2024-06-29 0001000228 hsic:TriMedIncMember 2024-04-01 0001000228 hsic:ShieldHealthcareIncMember 2023-10-02 0001000228 hsic:ShieldHealthcareIncMember 2023-10-02 2023-10-02 0001000228 hsic:TriMedIncMember 2024-04-01 2024-04-01 0001000228 hsic:ProductDevelopmentMember hsic:TriMedIncMember 2024-04-01 2024-04-01 0001000228 us-gaap:TrademarksAndTradeNamesMember hsic:TriMedIncMember 2024-04-01 2024-04-01 0001000228 us-gaap:InProcessResearchAndDevelopmentMember hsic:TriMedIncMember 2024-04-01 2024-04-01 0001000228 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember srt:MaximumMember 2024-06-29 0001000228 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-12-31 2024-06-29 0001000228 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2024-06-29 0001000228 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember hsic:CustomerRelationshipsAndListsMember 2024-06-29 0001000228 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember hsic:ProductDevelopmentMember 2024-06-29 0001000228 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember hsic:CustomerRelationshipsAndListsMember 2023-12-31 2024-06-29 0001000228 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember hsic:ProductDevelopmentMember 2023-12-31 2024-06-29 0001000228 hsic:ShieldHealthcareIncMember 2023-12-31 2024-06-29 0001000228 hsic:ShieldHealthcareIncMember 2023-12-30 0001000228 srt:RestatementAdjustmentMember hsic:ShieldHealthcareIncMember 2024-06-29 0001000228 hsic:ShieldHealthcareIncMember 2024-06-29 0001000228 hsic:ShieldHealthcareIncMember 2023-01-01 2023-12-30 0001000228 srt:RestatementAdjustmentMember hsic:ShieldHealthcareIncMember 2023-12-31 2024-06-29 0001000228 hsic:CustomerRelationshipsAndListsMember hsic:ShieldHealthcareIncMember 2023-10-02 2023-10-02 0001000228 hsic:SINImplantSystemMember 2023-12-31 2024-06-29 0001000228 hsic:SINImplantSystemMember 2023-12-30 0001000228 srt:RestatementAdjustmentMember hsic:SINImplantSystemMember 2024-06-29 0001000228 hsic:SINImplantSystemMember 2024-06-29 0001000228 hsic:SINImplantSystemMember 2023-01-01 2023-12-30 0001000228 hsic:CustomerRelationshipsAndListsMember hsic:SINImplantSystemMember 2023-07-05 2023-07-05 0001000228 hsic:ProductDevelopmentMember hsic:SINImplantSystemMember 2023-07-05 2023-07-05 0001000228 us-gaap:TrademarksAndTradeNamesMember hsic:SINImplantSystemMember 2023-07-05 2023-07-05 0001000228 hsic:September2023ThroughJune2024Member 2023-12-31 2024-06-29 0001000228 hsic:September2024ThroughJune2026Member 2023-12-31 2024-06-29 0001000228 us-gaap:InterestRateSwapMember hsic:TermCreditAgreementMember 2024-06-29 0001000228 us-gaap:RoyaltyAgreementsMember hsic:InternetBrandsIncMember 2024-03-31 2024-06-29 0001000228 us-gaap:RoyaltyAgreementsMember hsic:InternetBrandsIncMember 2023-04-02 2023-07-01 0001000228 us-gaap:RoyaltyAgreementsMember hsic:InternetBrandsIncMember 2023-01-01 2023-07-01 0001000228 hsic:InternetBrandsIncMember 2024-06-29 0001000228 srt:MinimumMember hsic:EmployeesAndMinorityShareholdersMember 2024-06-29 0001000228 srt:MaximumMember hsic:EmployeesAndMinorityShareholdersMember 2024-06-29 0001000228 hsic:EmployeesAndMinorityShareholdersMember 2024-06-29 0001000228 hsic:EmployeesAndMinorityShareholdersMember hsic:OperatingLeaseLiabilitiesCurrentMember hsic:RelatedPartyConcentrationRiskMember 2023-12-31 2024-06-29 0001000228 hsic:EmployeesAndMinorityShareholdersMember hsic:OperatingLeaseLiabilitiesNoncurrentMember hsic:RelatedPartyConcentrationRiskMember 2023-12-31 2024-06-29 0001000228 hsic:CyberIncidentMember 2024-03-31 2024-06-29 0001000228 hsic:CyberIncidentMember 2023-12-31 2024-06-29 0001000228 hsic:OtherShortTermCreditLinesMember 2023-12-31 2024-06-29 0001000228 us-gaap:NoncompeteAgreementsMember us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2024-06-29 0001000228 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:TrademarksAndTradeNamesMember 2024-06-29 0001000228 us-gaap:NoncompeteAgreementsMember us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-12-31 2024-06-29 0001000228 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:TrademarksAndTradeNamesMember 2023-12-31 2024-06-29 0001000228 us-gaap:TrademarksAndTradeNamesMember hsic:ShieldHealthcareIncMember 2023-10-02 2023-10-02 0001000228 us-gaap:RevolvingCreditFacilityMember 2023-01-01 2023-12-30 0001000228 hsic:HealthCareDistributionMember hsic:SeveranceAndEmployeeRelatedCostsMember 2023-04-02 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:AcceleratedDepreciationAndAmortizationMember 2023-04-02 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:ExitAndOtherRelatedCostsMember 2023-04-02 2023-07-01 0001000228 hsic:TechnologyAndValueAddedServicesMember hsic:SeveranceAndEmployeeRelatedCostsMember 2023-04-02 2023-07-01 0001000228 hsic:TechnologyAndValueAddedServicesMember hsic:AcceleratedDepreciationAndAmortizationMember 2023-04-02 2023-07-01 0001000228 hsic:SeveranceAndEmployeeRelatedCostsMember 2023-04-02 2023-07-01 0001000228 hsic:AcceleratedDepreciationAndAmortizationMember 2023-04-02 2023-07-01 0001000228 hsic:ExitAndOtherRelatedCostsMember 2023-04-02 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:SeveranceAndEmployeeRelatedCostsMember 2023-01-01 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:AcceleratedDepreciationAndAmortizationMember 2023-01-01 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:ExitAndOtherRelatedCostsMember 2023-01-01 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:DisposalOfBusinessMember 2023-01-01 2023-07-01 0001000228 hsic:TechnologyAndValueAddedServicesMember hsic:SeveranceAndEmployeeRelatedCostsMember 2023-01-01 2023-07-01 0001000228 hsic:TechnologyAndValueAddedServicesMember hsic:AcceleratedDepreciationAndAmortizationMember 2023-01-01 2023-07-01 0001000228 hsic:TechnologyAndValueAddedServicesMember hsic:ExitAndOtherRelatedCostsMember 2023-01-01 2023-07-01 0001000228 hsic:SeveranceAndEmployeeRelatedCostsMember 2023-01-01 2023-07-01 0001000228 hsic:AcceleratedDepreciationAndAmortizationMember 2023-01-01 2023-07-01 0001000228 hsic:ExitAndOtherRelatedCostsMember 2023-01-01 2023-07-01 0001000228 hsic:DisposalOfBusinessMember 2023-01-01 2023-07-01 0001000228 hsic:HealthCareDistributionMember hsic:SeveranceAndEmployeeRelatedCostsMember 2024-03-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:AcceleratedDepreciationAndAmortizationMember 2024-03-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:ExitAndOtherRelatedCostsMember 2024-03-31 2024-06-29 0001000228 hsic:TechnologyAndValueAddedServicesMember hsic:SeveranceAndEmployeeRelatedCostsMember 2024-03-31 2024-06-29 0001000228 hsic:SeveranceAndEmployeeRelatedCostsMember 2024-03-31 2024-06-29 0001000228 hsic:AcceleratedDepreciationAndAmortizationMember 2024-03-31 2024-06-29 0001000228 hsic:ExitAndOtherRelatedCostsMember 2024-03-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:SeveranceAndEmployeeRelatedCostsMember 2023-12-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:AcceleratedDepreciationAndAmortizationMember 2023-12-31 2024-06-29 0001000228 hsic:HealthCareDistributionMember hsic:ExitAndOtherRelatedCostsMember 2023-12-31 2024-06-29 0001000228 hsic:TechnologyAndValueAddedServicesMember hsic:SeveranceAndEmployeeRelatedCostsMember 2023-12-31 2024-06-29 0001000228 hsic:SeveranceAndEmployeeRelatedCostsMember 2023-12-31 2024-06-29 0001000228 hsic:AcceleratedDepreciationAndAmortizationMember 2023-12-31 2024-06-29 0001000228 hsic:ExitAndOtherRelatedCostsMember 2023-12-31 2024-06-29 0001000228 srt:MinimumMember us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2024-06-29 0001000228 srt:MinimumMember hsic:USTradeAccountsReceivableSecuritizationMember 2023-12-31 2024-06-29 0001000228 srt:MaximumMember hsic:USTradeAccountsReceivableSecuritizationMember 2023-12-31 2024-06-29 0001000228 srt:ScenarioForecastMember 2024-06-30 2024-12-28 0001000228 hsic:Other2023AcquisitionsMember 2024-03-31 2024-06-29 0001000228 hsic:Other2023AcquisitionsMember 2023-12-31 2024-06-29 iso4217:USD xbrli:pure xbrli:shares iso4217:USD xbrli:shares hsic:number hsic:segments hsic:countries hsic:claims
 
 
 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
10-Q
(Mark One)
 
QUARTERLY
 
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the
quarterly
 
period ended
June 29, 2024
or
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
 
ACT
 
OF 1934
For the transition period from ____________ to ____________
Commission File Number:
 
0-27078
HENRY SCHEIN, INC.
(Exact name of registrant as specified in its charter)
Delaware
11-3136595
(State or other jurisdiction of
(I.R.S. Employer Identification No.)
incorporation or organization)
135 Duryea Road
Melville
,
New York
(Address of principal executive offices)
11747
(Zip Code)
(
631
)
843-5500
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $.01 per share
HSIC
The
Nasdaq
 
Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required
 
to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
 
shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the
 
past 90 days.
Yes
 
No
 
Indicate by check mark whether the registrant has submitted electronically every
 
Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during
 
the preceding 12 months (or for such shorter period
that the registrant was required to submit such files).
Yes
 
No
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growth company.
 
See the definitions of “large accelerated filer,”
 
“accelerated filer,”
“smaller reporting company,”
 
and “emerging growth company”
 
in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
 
 
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
 
for
complying with any new or revised financial accounting standards provided
 
pursuant to Section 13(a) of the Exchange Act.
 
Indicate by check mark whether the registrant is a shell company (as defined
 
in Rule 12b-2 of the Exchange Act).
Yes
 
No
 
As of July 29, 2024,
there were
126,707,799
 
shares of the registrant’s common stock outstanding.
 
HENRY SCHEIN, INC.
INDEX
Page
3
4
5
6
7
 
8
9
9
10
11
12
13
14
19
21
24
25
26
28
30
30
32
32
33
34
50
51
52
52
52
52
53
54
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See accompanying notes.
3
PART
 
I. FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED
 
FINANCIAL STATEMENTS
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions,
 
except share data)
June 29,
December 30,
2024
2023
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents
 
$
138
$
171
Accounts receivable, net of allowance for credit losses of $
82
 
and $
83
 
(1)
1,559
1,863
Inventories, net of reserves of $
145
 
and $
192
1,657
1,815
Prepaid expenses and other
 
587
639
Total current assets
 
3,941
4,488
Property and equipment, net
 
518
498
Operating lease right-of-use assets
304
325
Goodwill
 
3,905
3,875
Other intangibles, net
 
1,081
916
Investments and other
502
471
Total assets
 
$
10,251
$
10,573
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND
STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
 
$
867
$
1,020
Bank credit lines
 
505
264
Current maturities of long-term debt
 
106
150
Operating lease liabilities
75
80
Accrued expenses:
Payroll and related
 
279
332
Taxes
 
150
137
Other
 
567
700
Total current liabilities
 
2,549
2,683
Long-term debt (1)
1,891
1,937
Deferred income taxes
 
115
54
Operating lease liabilities
261
310
Other liabilities
 
431
436
Total liabilities
 
5,247
5,420
Redeemable noncontrolling interests
 
856
864
Commitments and contingencies
 
(nil)
(nil)
Stockholders' equity:
Preferred stock, $
0.01
 
par value,
1,000,000
 
shares authorized,
none
 
outstanding
-
-
Common stock, $
0.01
 
par value,
480,000,000
 
shares authorized,
127,080,545
 
outstanding on June 29, 2024 and
129,247,765
 
outstanding on December 30, 2023
1
1
Additional paid-in capital
-
-
Retained earnings
 
3,803
3,860
Accumulated other comprehensive loss
 
(292)
(206)
Total Henry Schein, Inc. stockholders' equity
3,512
3,655
Noncontrolling interests
636
634
Total stockholders' equity
 
4,148
4,289
Total liabilities, redeemable noncontrolling
 
interests and stockholders' equity
$
10,251
$
10,573
(1)
Amounts presented include balances held by our consolidated variable interest entity (“VIE”).
 
At June 29, 2024 and December 30,
2023, includes trade accounts receivable of $
330
 
million and $
284
 
million, respectively, and long-term debt of $
195
 
million and
$
210
 
million, respectively.
 
See
 
for further information.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See accompanying notes.
4
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS
 
OF INCOME
(in millions,
 
except share and per share data)
(unaudited)
Three Months Ended
Six Months Ended
June 29,
July 1,
June 29,
July 1,
2024
2023
2024
2023
Net sales
 
$
3,136
$
3,100
$
6,308
$
6,160
Cost of sales
 
2,118
2,125
4,278
4,219
Gross profit
 
1,018
975
2,030
1,941
Operating expenses:
 
Selling, general and administrative
 
781
707
1,572
1,424
Depreciation and amortization
63
49
124
93
Restructuring costs
 
15
18
25
48
Operating income
 
159
201
309
376
Other income (expense):
 
Interest income
 
6
3
11
6
Interest expense
 
(32)
(19)
(62)
(33)
Other, net
 
(1)
1
1
-
Income before taxes, equity in earnings of affiliates and
noncontrolling interests
132
186
259
349
Income taxes
 
(33)
(41)
(65)
(80)
Equity in earnings of affiliates, net of tax
 
6
3
9
7
Net income
 
105
148
203
276
Less: Net income attributable to noncontrolling interests
 
(1)
(8)
(6)
(15)
Net income attributable to Henry Schein, Inc.
 
$
104
$
140
$
197
$
261
Earnings per share attributable to Henry Schein, Inc.:
 
Basic
 
$
0.81
$
1.07
$
1.53
$
1.99
Diluted
 
$
0.80
$
1.06
$
1.52
$
1.97
Weighted-average common
 
shares outstanding:
 
Basic
 
127,784,380
130,905,899
128,252,628
131,136,450
Diluted
 
128,646,506
131,873,174
129,206,780
132,465,749
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See accompanying notes.
5
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS
 
OF COMPREHENSIVE INCOME
(in millions)
 
(unaudited)
Three Months Ended
Six Months Ended
June 29,
July 1,
June 29,
July 1,
2024
2023
2024
2023
Net income
$
105
$
148
$
203
$
276
Other comprehensive income, net of tax:
Foreign currency translation gain (loss)
(62)
3
(116)
28
Unrealized gain (loss) from hedging activities
 
4
(1)
15
(4)
Other comprehensive income (loss), net of tax
(58)
2
(101)
24
Comprehensive income
 
47
150
102
300
Comprehensive income attributable to noncontrolling interests:
 
Net income
(1)
(8)
(6)
(15)
Foreign currency translation loss (gain)
5
1
15
(1)
Comprehensive (income) loss attributable to noncontrolling
interests
 
4
(7)
9
(16)
Comprehensive income attributable to Henry Schein, Inc.
 
$
51
$
143
$
111
$
284
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See accompanying notes.
6
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENT
 
OF CHANGES IN
 
STOCKHOLDERS’ EQUITY
(in millions, except share data)
(unaudited)
Accumulated
Common Stock
Additional
Other
Total
$0.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'
Shares
Amount
Capital
Earnings
Income / (Loss)
 
Interests
Equity
Balance, March 30, 2024
128,480,909
$
1
$
-
$
3,838
$
(239)
$
637
$
4,237
Net income (excluding loss of $
3
 
attributable to Redeemable
noncontrolling interests)
-
-
-
104
-
4
108
Foreign currency translation loss (excluding loss of $
5
attributable to Redeemable noncontrolling interests)
-
-
-
-
(57)
-
(57)
Unrealized gain from hedging activities,
net of tax of $
2
-
-
-
-
4
-
4
Distributions to noncontrolling shareholders
-
-
-
-
-
(5)
(5)
Change in fair value of redeemable securities
-
-
(39)
-
-
-
(39)
Noncontrolling interests and adjustments related to
business acquisitions
-
-
(11)
-
-
-
(11)
Repurchase and retirement of common stock
(1,415,706)
-
(14)
(87)
-
-
(101)
Stock issued upon exercise of stock options
4,301
-
1
-
-
-
1
Stock-based compensation expense
15,339
-
12
-
-
-
12
Shares withheld for payroll taxes
(4,298)
-
(1)
-
-
-
(1)
Transfer of charges in excess of
 
capital
-
-
52
(52)
-
-
-
Balance, June 29, 2024
127,080,545
$
1
$
-
$
3,803
$
(292)
$
636
$
4,148
Accumulated
Common Stock
Additional
Other
Total
$0.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'
Shares
Amount
Capital
Earnings
Income / (Loss)
 
Interests
Equity
Balance, April 1, 2023
131,196,783
$
1
$
-
$
3,684
$
(213)
$
655
$
4,127
Net income (excluding $
5
 
attributable to Redeemable
noncontrolling interests)
-
-
-
140
-
3
143
Foreign currency translation gain (excluding loss of $
1
attributable to Redeemable noncontrolling interests)
-
-
-
-
4
-
4
Unrealized loss from hedging activities,
including tax benefit of $
1
-
-
-
-
(1)
-
(1)
Distributions to noncontrolling shareholders
-
-
-
-
-
(27)
(27)
Change in fair value of redeemable securities
-
-
(17)
-
-
-
(17)
Noncontrolling interests and adjustments related to
business acquisitions
-
-
1
-
-
(5)
(4)
Repurchase and retirement of common stock
(638,095)
-
(7)
(44)
-
-
(51)
Stock-based compensation expense
20,598
-
14
-
-
-
14
Stock issued upon exercise of stock options
5,081
-
-
-
-
-
-
Shares withheld for payroll taxes
(6,671)
-
(3)
-
-
-
(3)
Settlement of stock-based compensation awards
(890)
-
1
-
-
-
1
Transfer of charges in excess of
 
capital
-
-
11
(11)
-
-
-
Balance, July 1, 2023
130,576,806
$
1
$
-
$
3,769
$
(210)
$
626
$
4,186
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See accompanying notes.
7
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENT
 
OF CHANGES IN
 
STOCKHOLDERS' EQUITY
(in millions, except share data)
(unaudited)
Accumulated
Common Stock
Additional
Other
Total
$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'
Shares
Amount
Capital
Earnings
Income / (Loss)
 
Interests
Equity
Balance, December 30, 2023
129,247,765
$
1
$
-
$
3,860
$
(206)
$
634
$
4,289
Net income (excluding loss of $
1
 
attributable to Redeemable
noncontrolling interests)
 
-
-
-
197
-
7
204
Foreign currency translation loss (excluding loss of $
15
attributable to Redeemable noncontrolling interests)
-
-
-
-
(101)
-
(101)
Unrealized gain from hedging activities,
net of tax of $
6
-
-
-
-
15
-
15
Distributions to noncontrolling shareholders
-
-
-
-
-
(5)
(5)
Change in fair value of redeemable securities
 
-
-
(81)
-
-
-
(81)
Noncontrolling interests and adjustments related to
business acquisitions
-
-
(10)
-
-
-
(10)
Repurchase and retirement of common stock
 
(2,414,434)
-
(24)
(152)
-
-
(176)
Stock issued upon exercise of stock options
 
25,240
-
2
-
-
-
2
Stock-based compensation expense
330,098
-
20
-
-
-
20
Shares withheld for payroll taxes
 
(108,163)
-
(9)
-
-
-
(9)
Settlement of stock-based compensation awards
39
-
-
-
-
-
-
Transfer of charges in excess of
 
capital
-
-
102
(102)
-
-
-
Balance, June 29, 2024
127,080,545
$
1
$
-
$
3,803
$
(292)
$
636
$
4,148
Accumulated
Common Stock
Additional
Other
Total
$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'
Shares
Amount
Capital
Earnings
Income / (Loss)
 
Interests
Equity
Balance, December 31, 2022
131,792,817
$
1
$
-
$
3,678
$
(233)
$
649
$
4,095
Net income (excluding $
9
 
attributable to Redeemable
noncontrolling interests)
 
-
-
-
261
-
6
267
Foreign currency translation gain (excluding gain of $
1
attributable to Redeemable noncontrolling interests)
-
-
-
-
27
-
27
Unrealized loss from hedging activities,
including tax benefit of $
2
-
-
-
-
(4)
-
(4)
Distributions to noncontrolling shareholders
-
-
-
-
-
(27)
(27)
Change in fair value of redeemable securities
-
-
(14)
-
-
-
(14)
Noncontrolling interests and adjustments related to
business acquisitions
-
-
1
-
-
(2)
(1)
Repurchase and retirement of common stock
 
(1,862,014)
-
(20)
(131)
-
-
(151)
Stock-based compensation expense
1,036,898
-
24
-
-
-
24
Stock issued upon exercise of stock options
 
15,860
-
1
-
-
-
1
Shares withheld for payroll taxes
 
(405,865)
-
(32)
-
-
-
(32)
Settlement of stock-based compensation awards
(890)
-
1
-
-
-
1
Transfer of charges in excess of
 
capital
-
-
39
(39)
-
-
-
Balance, July 1, 2023
130,576,806
$
1
$
-
$
3,769
$
(210)
$
626
$
4,186
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See accompanying notes.
8
HENRY SCHEIN, INC.
CONDENSED CONSOLIDATED STATEMENTS
 
OF CASH FLOWS
(in millions)
(unaudited)
Six Months Ended
June 29,
July 1,
2024
2023
Cash flows from operating activities:
Net income
 
$
203
$
276
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
 
147
111
Non-cash restructuring charges
6
10
Stock-based compensation expense
20
24
Provision for losses on trade and other accounts receivable
 
7
2
Benefit from deferred income taxes
(19)
(3)
Equity in earnings of affiliates
(9)
(7)
Distributions from equity affiliates
 
9
9
Changes in unrecognized tax benefits
 
3
3
Other
 
(9)
(9)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable
 
270
18
Inventories
 
107
163
Other current assets
 
50
(1)
Accounts payable and accrued expenses
 
(292)
(295)
Net cash provided by operating activities
493
301
Cash flows from investing activities:
Purchases of property and equipment
(78)
(68)
Payments related to equity investments and business acquisitions,
net of cash acquired
 
(181)
(251)
Proceeds from loan to affiliate
3
3
Capitalized software costs
(20)
(20)
Other
 
(5)
(4)
Net cash used in investing activities
 
(281)
(340)
Cash flows from financing activities:
Net change in bank credit lines
242
218
Proceeds from issuance of long-term debt
 
90
408
Principal payments for long-term debt
 
(177)
(366)
Proceeds from issuance of stock upon exercise of stock options
 
2
1
Payments for repurchases and retirement of common stock
 
(175)
(150)
Payments for taxes related to shares withheld for employee taxes
(8)
(33)
Distributions to noncontrolling shareholders
(28)
(6)
Acquisitions of noncontrolling interests in subsidiaries
 
(211)
(13)
Net cash provided by (used in) financing activities
(265)
59
Effect of exchange rate changes on cash and cash equivalents
20
-
Net change in cash and cash equivalents
(33)
20
Cash and cash equivalents, beginning of period
 
171
117
Cash and cash equivalents, end of period
 
$
138
$
137
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
9
Note 1 – Basis of Presentation
Our condensed consolidated financial statements include the accounts of Henry
 
Schein, Inc., and all of our
controlled subsidiaries (“we”, “us” and “our”).
 
All intercompany accounts and transactions are eliminated in
consolidation.
 
Investments in unconsolidated affiliates for which we have the ability to influence
 
the operating or
financial decisions are accounted for under the equity method.
 
Certain prior period amounts have been reclassified
to conform to the current period presentation.
 
These reclassifications, individually and in the aggregate, did
 
not
have a material impact on our condensed consolidated financial condition,
 
results of operations or cash flows.
Our accompanying unaudited condensed consolidated financial statements
 
have been prepared in accordance with
accounting principles generally accepted in the United States
 
(“U.S. GAAP”) for interim financial information and
with the instructions to Form 10-Q and Article 10 of Regulation S-X.
 
Accordingly, they do not include all of the
information and footnote disclosures required by U.S. GAAP for complete
 
financial statements.
The unaudited interim condensed consolidated financial statements should be
 
read in conjunction with the audited
consolidated financial statements and notes to the consolidated financial
 
statements contained in our Annual Report
on Form 10-K for the year ended December 30, 2023 and with the information
 
contained in our other publicly-
available filings with the Securities and Exchange Commission.
 
The condensed consolidated financial statements
reflect all adjustments considered necessary for a fair presentation of
 
the consolidated results of operations and
financial position for the interim periods presented.
 
All such adjustments are of a normal recurring nature.
 
The preparation of financial statements in conformity with accounting principles
 
generally accepted in the United
States requires us to make estimates and assumptions that affect the reported amounts of
 
assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
 
statements and the reported amounts of
revenues and expenses during the reporting period.
 
Actual results could differ from those estimates.
 
The results of
operations for the three and six months ended June 29, 2024 are not necessarily
 
indicative of the results to be
expected for any other interim period or for the year ending December
 
28, 2024.
Our condensed consolidated financial statements reflect estimates and
 
assumptions made by us that affect, among
other things, our goodwill, long-lived asset and definite-lived intangible
 
asset valuation; inventory valuation; equity
investment valuation; assessment of the annual effective tax rate; valuation of
 
deferred income taxes and income
tax contingencies; the allowance for doubtful accounts; hedging activity;
 
supplier rebates; measurement of
compensation cost for certain share-based performance awards and cash bonus
 
plans; and pension plan
assumptions.
We consolidate the results of operations and financial position of a trade accounts receivable securitization which
we consider a VIE because we are its primary beneficiary, as we have the power to direct activities that most
significantly affect its economic performance and have the obligation to absorb the
 
majority of its losses or
benefits.
 
For this VIE, the trade accounts receivable transferred
 
to the VIE are pledged as collateral to the related
debt.
 
The VIE’s creditors have recourse to us for losses on these trade accounts receivable.
 
At June 29, 2024 and
December 30, 2023, certain trade accounts receivable that can only be used
 
to settle obligations of this VIE were
$
330
 
million and $
284
 
million, respectively, and the liabilities of this VIE where the creditors have recourse to us
were $
195
 
million and $
210
 
million, respectively.
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
10
Note 2 – Significant Accounting Policies and Recently Issued Accounting
 
Standards
Significant Accounting Policies
 
There have been no material changes in our significant accounting policies during
 
the three and six months ended
June 29, 2024, as compared to the significant accounting policies described
 
in Item 8 of our Annual Report on
Form 10-K for the year ended December 30, 2023.
Recently Issued Accounting Standards
In March 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update
(“ASU”) 2024-01, “
Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and
Similar Awards,
” which clarifies how to determine whether a profit interest and
 
similar awards should be accounted
for as a share-based payment arrangement under Topic 718 or within the scope of other guidance.
 
The ASU
provides an illustrative example with multiple fact patterns and amends
 
the structure of paragraph 718-10-15-3 of
Topic 718 to improve its clarity and operability.
 
The guidance in ASU 2024-01 applies to all entities that
 
issue
profits interest awards as compensation to employees or nonemployees
 
in exchange for goods or services.
 
Entities
can apply the amendments either retrospectively to all periods presented
 
in the financial statements or prospectively
to profits interest awards granted or modified on or after the date
 
of adoption.
 
If prospective application is elected,
an entity must disclose the nature of and reason for the change in accounting principle
 
that resulted from the
adoption of the ASU.
 
This ASU is effective for fiscal years beginning after December 15, 2024,
 
including interim
periods within those fiscal years.
 
We do not expect that the requirements of ASU 2024 – 01 will have a material
impact on our consolidated financial statements.
In December 2023, FASB issued ASU 2023-09, “
Income Taxes (Topic
 
740): Improvements to Income Tax
Disclosures
,” which requires public business entities to disclose additional
 
information in specified categories with
respect to the reconciliation of the effective tax rate to the statutory rate for federal, state and
 
foreign income taxes.
 
It also requires greater detail about individual reconciling items in
 
the rate reconciliation to the extent the impact of
those items exceeds a specified threshold.
 
In addition to new disclosures associated with the rate reconciliation,
 
the
ASU requires information pertaining to taxes paid (net of refunds received)
 
to be disaggregated for federal, state
and foreign taxes and further disaggregated for specific jurisdictions
 
to the extent the related amounts exceed a
quantitative threshold.
 
The ASU also describes items that need to be disaggregated
 
based on their nature, which is
determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event
 
that
triggered the establishment of the reconciling item and the activity with which
 
the reconciling item is associated.
 
The ASU eliminates the historic requirement that entities disclose information
 
concerning unrecognized tax
benefits having a reasonable possibility of significantly increasing
 
or decreasing in the 12 months following the
reporting date.
 
This ASU is effective for annual periods beginning after December 15, 2024.
 
Early adoption is
permitted for annual financial statements that have not yet been
 
issued or made available for issuance.
 
This ASU
should be applied on a prospective basis; however, retrospective application is permitted.
 
We are currently
evaluating the impact that ASU 2023-09 will have on our consolidated
 
financial statements.
In November 2023, the FASB issued ASU 2023-07, “
Segment Reporting (Topic 280): Improvements to Reportable
Segments
,” which aims to improve financial reporting by requiring disclosure
 
of incremental segment information
on an annual and interim basis for all public entities to enable investors to
 
develop more decision-useful financial
analyses.
 
Currently, Topic
 
280 requires that a public entity disclose certain information about its
 
reportable
segments.
 
For example, a public entity is required to report a measure of
 
segment profit or loss that the chief
operating decision maker uses to assess segment performance and
 
make decisions about allocating resources.
 
Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization and
depletion expense, to be disclosed under certain circumstances.
 
The amendments in this ASU do not change or
remove those disclosure requirements and do not change how a public
 
entity identifies its operating segments,
aggregates those operating segments or applies the quantitative thresholds
 
to determine its reportable segments.
 
This ASU is effective for fiscal years beginning after December 15, 2023, and interim
 
periods within fiscal years
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
11
 
beginning after December 15, 2024.
 
Early adoption is permitted.
 
We are currently evaluating the impact that ASU
2023- 07 will have on our consolidated financial statements.
Note 3 – Cyber Incident
In October 2023 Henry Schein experienced a cyber incident that primarily
 
affected the operations of our North
American and European dental and medical distribution businesses.
 
Henry Schein One, our practice management
software, revenue cycle management and patient relationship management
 
solutions business, was not affected, and
our manufacturing businesses were mostly unaffected.
 
On November 22, 2023, we experienced a disruption of our
ecommerce platform and related applications, which was remediated.
During the three and six months ended June 29, 2024, we continued to
 
experience a residual impact of the cyber
events noted above relating primarily to decreased sales to episodic customers
 
(customers that had generally
registered a less continuous level of demand pre-incident).
During the three and six months ended June 29, 2024, we incurred $
3
 
million and $
8
 
million, respectively, of
expenses directly related to the cyber incident, mostly consisting of professional
 
fees.
 
We maintain cyber
insurance, subject to certain retentions and policy limitations.
 
With respect to the October 2023 cyber incident, we
have a $
60
 
million insurance policy, following a $
5
 
million retention.
 
During the three and six months ended June
29, 2024, we received insurance proceeds of $
10
 
million, representing a partial insurance recovery of losses
 
related
to the cyber incident.
 
The expenses and insurance recoveries related to the cyber
 
incident are included in the
selling, general and administrative line in our condensed consolidated
 
statements of income.
 
 
 
 
 
 
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
12
Note 4 – Net Sales from Contracts with Customers
Net sales are recognized in accordance with policies disclosed in Item
 
8 of our Annual Report on Form 10-K for
the year ended December 30, 2023.
Disaggregation of Net Sales
The following table disaggregates our net sales by reportable and operating segment
 
and geographic area:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
Six Months Ended
June 29, 2024
June 29, 2024
North
America
International
Global
North
America
International
Global
Net sales:
Health care distribution
 
Dental
 
$
1,129
$
795
$
1,924
$
2,232
$
1,606
$
3,838
Medical
 
970
28
998
1,984
55
2,039
Total health care distribution
2,099
823
2,922
4,216
1,661
5,877
Technology
 
and value-added services
 
186
28
214
375
56
431
Total net sales
$
2,285
$
851
$
3,136
$
4,591
$
1,717
$
6,308
Three Months Ended
 
Six Months Ended
July 1, 2023
July 1, 2023
North
America
International
Global
North
America
International
Global
Net sales:
Health care distribution
 
Dental
 
$
1,169
$
788
$
1,957
$
2,313
$
1,542
$
3,855
Medical
 
925
25
950
1,876
45
1,921
Total health care distribution
2,094
813
2,907
4,189
1,587
5,776
Technology
 
and value-added services
 
168
25
193
334
50
384
Total net sales
$
2,262
$
838
$
3,100
$
4,523
$
1,637
$
6,160
Contract Liabilities
At June 29, 2024,
 
December 30, 2023,
 
and December 31, 2022, the current and non-current contract
 
liabilities were
$
77
 
million and $
8
 
million; $
89
 
million and $
9
 
million; and $
86
 
million and $
8
 
million, respectively.
 
During the
six months ended June 29, 2024, we recognized, in net sales, $
55
 
million of the amount that was previously
deferred at December 30, 2023.
 
During the six months ended July 1, 2023, we recognized in net sales
 
$
56
 
million
of the amount that was previously deferred at December 31, 2022.
 
Current contract liabilities are included in
accrued expenses: other and the non-current contract liabilities are
 
included in other liabilities within our
consolidated balance sheets.
 
 
 
 
 
 
 
 
 
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
13
 
Note 5
 
Segment Data
We conduct our business through
two
 
reportable segments: (i) health care distribution and (ii) technology and
value-added services.
 
These segments offer different products and services to the same customer base.
 
Our global
dental businesses serve office-based dental practitioners, dental laboratories, schools, government
 
and other
institutions.
 
Our medical businesses serve physician offices, urgent care centers, ambulatory care sites,
 
emergency
medical technicians, dialysis centers, home health, federal and state governments
 
and large enterprises, such as
group practices, and integrated delivery networks, among other providers
 
across a wide range of specialties.
 
Our
dental and medical groups serve practitioners in
33
 
countries worldwide.
The health care distribution reportable segment aggregates our global dental
 
and medical operating segments.
 
This
segment distributes consumable products, dental specialty products (including
 
implant, orthodontic and endodontic
products),
 
small equipment, laboratory products, large equipment, equipment repair
 
services, branded and generic
pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal
 
protective
equipment (“PPE”) products, vitamins and orthopedic implants.
 
Our global technology and value-added services reportable segment provides
 
software, technology and other value-
added services to health care practitioners.
 
Our technology offerings include practice management software
systems for dental and medical practitioners.
 
Our value-added practice solutions include practice consultancy,
education, revenue cycle management and financial services on a non-recourse
 
basis, e-services, continuing
education services for practitioners,
 
practice technology, network and hardware services, and other services.
The following tables present information about our reportable and operating
 
segments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
Six Months Ended
June 29,
July 1,
June 29,
July 1,
2024
2023
2024
2023
Net sales:
Health care distribution
(1)
Dental
 
$
1,924
$
1,957
$
3,838
$
3,855
Medical
 
998
950
2,039
1,921
Total health care distribution
2,922
2,907
5,877
5,776
Technology
 
and value-added services
(2)
214
193
431
384
Total
 
$
3,136
$
3,100
$
6,308
$
6,160
(1)
Consists of consumable products, dental specialty products (including implant, orthodontic and endodontic products), small
equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical
products, diagnostic tests, infection-control products, PPE products, vitamins and orthopedic implants.
(2)
Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing
education services for practitioners, practice technology, network and hardware services, and other services.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
Six Months Ended
June 29,
July 1,
June 29,
July 1,
2024
2023
2024
2023
Operating Income:
Health care distribution
 
$
146
$
166
$
272
$
311
Technology
 
and value-added services
 
13
35
37
65
Total
$
159
$
201
$
309
$
376
 
 
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
14
Note 6
 
Business Acquisitions
Our acquisition strategy is focused on investments in companies that
 
add new customers and sales teams, increase
our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we
have already invested in businesses), and finally, those that enable us to access new products and technologies.
Acquisition of TriMed
On April 1, 2024, we acquired a
60
% voting equity interest in TriMed Inc. (“TriMed”), a global developer of
solutions for the orthopedic treatment of lower and upper extremities, headquartered
 
in California.
The following table aggregates
 
the preliminary estimated fair value, as of the date of acquisition, of
 
consideration
paid and net assets acquired in the TriMed acquisition:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2024
Acquisition consideration:
Cash
$
141
Deferred consideration
22
Redeemable noncontrolling interests
153
Total consideration
$
316
Identifiable assets acquired and liabilities assumed:
Current assets
$
36
Intangible assets
221
Other noncurrent assets
10
Current liabilities
(9)
Deferred income taxes
(62)
Other noncurrent liabilities
(6)
Total identifiable
 
net assets
190
Goodwill
126
Total net assets acquired
$
316
Goodwill is a result of synergies that are expected to originate from the acquisition as well as
 
the expected growth
potential of TriMed.
 
The acquired goodwill is not deductible for tax purposes.
 
The following table summarizes the
preliminary identifiable intangible assets acquired as part of the acquisition
 
of TriMed:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2024
Weighted Average
 
Useful
Lives (in years)
Product development
$
204
9
Trademarks / Tradenames
9
7
In process research & development
8
-
Total
$
221
The accounting for the acquisition of TriMed has not been completed in several areas,
 
including but not limited to
pending assessments of accounts receivable, inventory, intangible assets, right-of-use lease assets, accrued
liabilities, income and non-income based taxes and valuation of redeemable
 
noncontrolling interests.
 
To assist
management in the allocation, we engaged valuation specialists to
 
prepare appraisals.
 
We will finalize the amounts
recognized as the information necessary to complete the analysis
 
is obtained.
 
We expect to finalize these amounts
as soon as possible but no later than one year from the acquisition date.
The pro forma financial information has not been presented because the
 
impact of the TriMed acquisition during
the three and six months ended June 29, 2024 was immaterial to our
 
condensed consolidated financial statements.
 
 
 
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
15
Other 2024 Acquisitions
During the six months ended June 29, 2024, we acquired companies
 
within the health care distribution and
technology and value-added services segments.
 
Our acquired ownership interest in these companies range from
51
% to
100
%.
 
Total consideration for these acquisitions was $
23
 
million.
 
Net assets acquired primarily consisted
of $
13
 
million of goodwill and $
14
 
million of intangible assets.
 
The intangible assets acquired consisted of
customer relationships and lists of $
7
 
million, product development of $
4
 
million, non-compete agreements of $
2
million and trademarks and tradenames of $
1
 
million.
 
Weighted average useful lives for these acquired intangible
assets were
10
 
years,
10
 
years,
5
 
years and
5
 
years, respectively.
Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions
 
are expected to provide
for us, as well as the expected growth potential.
 
Approximately half of the acquired goodwill is deductible
 
for tax
purposes.
 
The impact of these acquisitions, individually and in the aggregate, was
 
not considered material to our condensed
consolidated financial statements.
2023 Acquisitions
Acquisition of Shield Healthcare
On October 2, 2023 we acquired a
90
% voting equity interest in Shield Healthcare, Inc. (“Shield”), a supplier
 
of
homecare medical products delivered directly to patients in their homes,
 
for consideration of $
348
 
million
(including cash paid of $
289
 
million, deferred consideration of $
22
 
million and redeemable noncontrolling interests
of $
37
 
million).
 
Shield expands our existing medical business by delivering
 
a diverse range of products, including
items such as incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes supplies.
 
Additionally, Shield offers continuous glucose monitoring devices directly to patients in their homes.
During the quarter ended June 29, 2024, we completed the accounting for our
 
acquisition of Shield.
 
The following
table aggregates the final fair value, as of the date of the acquisition, of consideration
 
paid and net assets acquired
in the Shield acquisition, including measurement period adjustments recorded
 
through June 29, 2024:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preliminary
Allocation as of
December 30, 2023
Measurement
Period
Adjustments
Final Allocation
Acquisition consideration:
Cash
$
286
$
3
$
289
Deferred consideration
43
(21)
22
Redeemable noncontrolling interests
37
-
37
Total consideration
$
366
$
(18)
$
348
Identifiable assets acquired and liabilities assumed:
Current assets
$
41
$
-
$
41
Intangible assets
166
-
166
Other noncurrent assets
14
2
16
Current liabilities
(24)
-
(24)
Deferred income taxes
(41)
(2)
(43)
Other noncurrent liabilities
(7)
-
(7)
Total identifiable
 
net assets
149
-
149
Goodwill
217
(18)
199
Total net assets acquired
$
366
$
(18)
$
348
 
 
 
 
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
16
Goodwill is a result of synergies that are expected to originate from the acquisition as well as
 
the expected growth
potential of Shield.
 
The acquired goodwill is not deductible for tax purposes.
 
The following table summarizes the identifiable intangible assets acquired
 
as part of the acquisition of Shield:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2023
Weighted Average
 
Useful Lives
(in years)
Customer relationships and lists
$
156
12
Trademarks / Tradenames
10
5
Total
$
166
The pro forma financial information has not been presented because the impact
 
of the Shield acquisition was
immaterial to our consolidated financial statements.
Acquisition of S.I.N. Implant System
On July 5, 2023, we acquired a
100
% voting equity interest in S.I.N. Implant System (“S.I.N.”) for consideration of
$
329
 
million.
 
Based in São Paulo, S.I.N. manufactures an extensive line of products
 
to perform dental implant
procedures and is focused on advancing the development of value-priced dental
 
implants.
 
In 2023, S.I.N. expanded
the distribution of its products into the United States and other international
 
markets
.
During the quarter ended June 29, 2024, we completed the accounting for our
 
acquisition of S.I.N.
 
The following
table aggregates the final fair value, as of the date of acquisition, of consideration
 
paid and net assets acquired in
the S.I.N. acquisition, including measurement period adjustments: